Suchergebnisse - "Mushti, Sirisha L"

PubPharm (9)

1

Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer : an FDA pooled analysis

enthalten in: The Lancet. Oncology | 2024

von Goulart, B. | Mushti, S. | Chatterjee, S. | +5

2

FDA Approval Summary : Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Gandhy, S. | Casak, S. | Mushti, S. | +17

3

FDA Approval Summary : Ripretinib for Advanced Gastrointestinal Stromal Tumor

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Kumar, V. | Doros, L. | Thompson, M. | +10

4

FDA Approval Summary : Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Casak, S. | Marcus, L. | Fashoyin-Aje, L. | +10

5

FDA Approval Summary : Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Bradford, D. | Larkins, E. | Mushti, S. | +20

6

Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression : Response Assessments for Cancer Immunotherapy

enthalten in: Current oncology reports | 2020

von Mushti, S. | Mulkey, F. | Tang, S. | +9

7

Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy

enthalten in: Current oncology reports | 2020

von Mushti, S. | Mulkey, F. | Tang, S. | +9

8

Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy

enthalten in: Current oncology reports | 2020

von Mushti, S. | Mulkey, F. | Tang, S. | +9

9

Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2018

von Mushti, S. | Mulkey, F. | Sridhara, R.

CommentIn: Clin Cancer Res. 2018 May 15;24(10):2239-2240. - PMID 29440189

1
[1]